LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Acadia Healthcare to Participate in November Conferences

November 09, 2023 | Last Trade: US$45.06 1.28 2.92

FRANKLIN, Tenn. / Nov 09, 2023 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two conferences in November.

On Tuesday, November 14, 2023, the Company will participate in the Wolfe Research Healthcare Conference 2023, which is being held November 14 - 15, 2023, in New York, New York. The Company’s presentation will be at 1:15 p.m. Eastern Time / 12:15 p.m. Central Time.

On Thursday, November 16, 2023, the Company will participate in the Stephens Annual Investment Conference, which is being held November 14 - 16, 2023, in Nashville, Tennessee. The Company’s presentation will be at 2:00 p.m. Eastern Time / 1:00 p.m. Central Time.

The live webcast of both presentations webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2023, Acadia operated a network of 253 behavioral healthcare facilities with approximately 11,100 beds in 39 states and Puerto Rico. With approximately 23,000 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page